Navigation Links
Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Date:5/4/2010

RICHMOND, Calif., May 4 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic™ development programs and an overview of the company's business strategy at two investor conferences during the month of May:

  • The Ninth Annual JMP Securities Research Conference in San Francisco, at 2:00 pm PT on Monday, May 10.
  • The Bank of America Merrill Lynch Health Care Conference in New York City, at 4:20 pm ET on Wednesday, May 12.

Live webcasts of the presentations will be available on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. A replay of each presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification.  The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
2. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
3. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
4. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
5. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
6. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
7. Sangamo Announces Pricing of Public Offering of Common Stock
8. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
9. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
10. Sangamos Zinc Finger Nuclease Technology Used to Efficiently Modify Human Stem Cells
11. Sangamo BioSciences Reports Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... , Aug. 16, 2017  Kingfisher Talent, the ... development, and Virdis Group, global executive search specialists in the ... enables clients to leverage the expertise and reach of both ... here in the Boston biotech hub, ... leadership talent throughout the US, Canada ...
(Date:8/15/2017)... ... August 15, 2017 , ... Any expert in stem ... compromised these disciplines for more than half a century. Despite their essential roles ... It is widely known that molecular tags developed for this purpose also tag other, ...
(Date:8/14/2017)... ... August 14, 2017 , ... Every year, millions ... in the antibody community have recently come together to address this antibody crisis ... laboratory. , The team at Thermo Fisher Scientific has ...
(Date:8/11/2017)... ... ... Algenist continues to disrupt the skincare industry with today’s debut of GENIUS ... is the key structural element skin needs to maintain its youthful appearance and Algenist ... First to market with proprietary collagen water active , ...
Breaking Biology Technology:
(Date:3/29/2017)... , March 29, 2017  higi, the health ... in North America , today announced ... and the acquisition of EveryMove. The new investment and ... set of tools to transform population health activities through ... lifestyle data. higi collects and secures data ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):